Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis

AIM: The Certolizumab–Optimal Prevention of joint damage for Early Rheumatoid Arthritis (C‐OPERA) study demonstrated that in methotrexate (MTX)‐naïve early RA patients with poor prognostic factors, 1‐year certolizumab pegol (CZP) therapy added to the first year of 2‐year optimized MTX therapy brings...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yoshiya, Atsumi, Tatsuya, Yamamoto, Kazuhiko, Takeuchi, Tsutomu, Yamanaka, Hisashi, Ishiguro, Naoki, Eguchi, Katsumi, Watanabe, Akira, Origasa, Hideki, Shoji, Toshiharu, Miyasaka, Nobuyuki, Koike, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065202/
https://www.ncbi.nlm.nih.gov/pubmed/31957303
http://dx.doi.org/10.1111/1756-185X.13780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065202/
https://www.ncbi.nlm.nih.gov/pubmed/31957303
http://dx.doi.org/10.1111/1756-185X.13780

Ejemplares similares